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Epitope Spreading Is Rarely Found in Pemphigus
Vulgaris by Large-Scale Longitudinal Study Using
Desmoglein 2–Based Swapped Molecules
Bungo Ohyama1,2, Koji Nishifuji2,3, Po Tak Chan2,4, Atsushi Kawaguchi5, Takuto Yamashita5, Norito Ishii1,
Takahiro Hamada1, Teruki Dainichi1, Hiroshi Koga1, Daisuke Tsuruta1, Masayuki Amagai2 and
Takashi Hashimoto1
Epitope spreading is involved in inducing and maintaining self-reactivity. Epitope spreading in pemphigus
vulgaris (PV), caused by IgG autoantibodies to desmoglein 3 (Dsg3) and Dsg1, was previously analyzed using
Dsg3/Dsg1 extracellular domain–swapped molecules. However, precise identification of the responsible
epitopes in each molecule by using only this method was problematic. In this study, we studied epitope
spreading in PV by a novel immunoprecipitation–immunoblot method using Dsg3 (or Dsg1)/Dsg2
domain–swapped molecules, which overcomes the problems associated with the previous approaches. We
analyzed the antigenic epitopes recognized by 212 sera collected from 53 PV patients at multiple disease stages.
The major epitopes were present at the N-terminal region of Dsgs and were unchanged over the course of the
disease in both anti-Dsg3 mucosal dominant-type PV and anti-Dsg3/Dsg1 mucocutaneous-type PV. These
N-terminal epitopes were calcium dependent. Circulating antibodies in paraneoplastic pemphigus and
pemphigus herpetiformis had unique epitope distributions, although the Dsg N-termini still contained the
major epitopes. These results suggest that, after onset, intramolecular and intermolecular epitope spreading
among extracellular domains on Dsg3 and Dsg1 is rare in PV and has no correlation with disease course.
Journal of Investigative Dermatology (2012) 132, 1158–1168; doi:10.1038/jid.2011.448; published online 26 January 2012
INTRODUCTION
Epitope spreading is a phenomenon in which immune
responses can spread over the disease course to recognize
epitopes that are different from the original target. If it occurs
in the same molecule, this is termed ‘‘intramolecular epitope
spreading’’ (Lehmann et al., 1992). When responses begin to
target epitopes on other proteins, this is termed ‘‘intermole-
cular epitope spreading’’ (Steinman and Conlon, 1997).
Accumulating evidence supports the epitope-spreading
hypothesis (McRae et al., 1995; Robinson et al., 2003;
McMahon et al., 2005; Chen et al., 2006). However, a
pathological role for epitope spreading was not demonstrated
in human diseases. One reason may be that it is difficult to
evaluate the responsible epitopes (Vanderlugt and Miller,
2002). In addition, published studies were small in scale
(Tuohy et al., 1997, 1999; Goebels et al., 2000; Jones et al.,
2003; O’Connor et al., 2005).
Pemphigus is caused by IgG autoantibodies against
desmogleins (Dsgs) (Amagai, 2003). Four isoforms of Dsgs
were described. Dsg1 is the autoantigen in pemphigus
foliaceus (PF) and mucocutaneous-type pemphigus vulgaris
(PV; Amagai et al., 1995; Stanley and Amagai, 2006). Dsg3 is
the autoantigen in mucocutaneous-type PV and mucosal
dominant-type PV (Amagai et al., 1991, 1994; Koch et al.,
1997; Mahoney et al., 1999). Pemphigus sera occasionally
contain Dsg4/Dsg1 cross-reacting IgG autoantibodies (Kljuic
et al., 2003; Whittock and Bower, 2003; Nagasaka et al.,
2004). No reactivity against Dsg2 was found in PF or PV sera
(Ota et al., 2003).
There were no definitive investigations elucidating in-
tramolecular epitope spreading in tissue-specific auto-
immune diseases, although some attempts were made for
epitopes within each domain of Dsg3 and Dsg1 in PV. These
relied on molecules constructed by combining the extra-
cellular (EC) domains of Dsg1 and Dsg3 (Futei et al., 2000;
Sekiguchi et al., 2001; Li et al., 2003; Salato et al., 2005).
However, these analyses had a limitation. Although most of
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the anti-Dsg3 IgG autoantibodies in PV did not cross-react
with Dsg1, one could not analyze anti-Dsg3 and anti-Dsg1
antibodies simultaneously in mucocutaneous-type PV by
using this method. We therefore generated domain-swapped
molecules comprising Dsg3 (or Dsg1) with Dsg2 as the
backbone, taking advantage of the fact that PV sera show no
reactivity with Dsg2. We defined epitope distribution and
intramolecular epitope spreading by immunoprecipitation–
immunoblotting (IP–IB) using 212 sera collected from 53 PV
patients, and showed that epitope spreading is rare in PV.
RESULTS
Generation of new domain-swapped molecules
We first generated Dsg1, Dsg2, and Dsg3 molecules with full-
length EC domains (Figure 1a). By replacing the five EC
domains of Dsg2 with the corresponding Dsg3, we obtained
a set of five new Dsg3/Dsg2 domain–swapped molecules as
secreted proteins, using the previously reported technique
(Chan et al., 2010; Figure 1a). The primers used in this study
are shown in Supplementary Table S1 online. Characteriza-
tion of Dsg1/Dsg2 domain–swapped molecules has been
detailed previously (Chan et al., 2010).
Immunoblotting of culture supernatants by anti-E tag mAb
Culture supernatants containing full-length EC domains of
Dsg1, Dsg2, and Dsg3, as well as the five Dsg3/Dsg2 and the
five Dsg1/Dsg2 domain–swapped molecules, were fraction-
ated by SDS-PAGE and immunoblotted with anti-E tag mAb.
Protein bands of the expected sizes were observed for the
unmodified Dsg1–3 and all 10 Dsg3/Dsg2 and Dsg1/Dsg2
domain–swapped molecules (Figure 1b and c).
Domain-swapped molecules of the N-terminal (EC1, EC2, and
EC3) but not C-terminal regions (EC4 and EC5) of Dsg1 and
Dsg3 are calcium dependent
We investigated whether domain-swapped molecules were
recognized by anti-Dsg1 or anti-Dsg3 IgG autoantibodies in a
calcium-dependent manner using EDTA treatment. Domain-
swapped molecules were left untreated or were treated with
EDTA, and then immunoprecipitated with anti-Dsg1 or anti-
Dsg3 IgG antibodies recognizing each of the five EC domains
of Dsg1 or Dsg3. EDTA treatment abolished the reactivity of
both anti-Dsg1 and anti-Dsg3 IgG to the respective EC1–3,
but not to the EC4–5 domains of Dsg1 and Dsg3. (Figure 1d.
Note the diminishment of the EC1-swapped molecule with-
out prosequence). Thus, anti-Dsg1 and anti-Dsg3 IgG
antibodies recognize calcium-dependent epitopes on the
EC1–3 domains of Dsg1 and Dsg3, whereas recognition of
epitopes on the EC4–5 domains is calcium independent.
Most anti-Dsg3 IgG autoantibodies recognize N-terminal
regions on the Dsg3 EC domains
We analyzed the Dsg3 epitopes recognized by 212 serum
samples from 53 cases of mucosal dominant-type PV and
mucocutaneous-type PV over the disease course. All 212 sera
reacted with the full-length EC domain of Dsg3, but none
with that of Dsg2 (Figure 2a). Of these 212 PV sera, 193
(91.0%) reacted with EC1, 151 (71.2%) with EC2, 107
(50.5%) with EC3, 40 (18.9%) with EC4, and 26 (12.3%) with
the EC5 domain of Dsg3. The reactivity of PV sera to the EC1
domain of Dsg3 was significantly higher than that to the
EC2–EC5 domains (Po0.0001). The reactivity of PV sera to
the EC2 domain of Dsg3 was also significantly higher than
that to the EC3–5 domains (Po0.0001).
Further, we determined the epitope profiles recognized by
these 212 PV sera obtained at different disease stages: active,
moderate, and remission (Table 1a). The results revealed that
the major epitope remained on the N-terminal domain of
Dsg3 at every clinical stage. A total of 164 sera (77.4%)
recognized multiple EC domains of Dsg3 (Table 1b). Of
these, 63 (29.7%) reacted with two, 64 (30.2%) with three, 34
(16.0%) with four, and only 3 (1.4%) with all five EC
domains. In contrast, the remaining 48 sera (22.6%) reacted
with only one of the EC domains of Dsg3; specifically, 40
(18.9%) reacted with the EC1 domain, 5 (2.4%) only with
EC2, and 3 (1.4%) only with EC3 (Table 1c). No sera reacted
only with the EC4 or EC5 domain of Dsg3. The number of
epitopes recognized by each anti-Dsg3 IgG autoantibody
correlated with an increasing ELISA index score (P¼0.0011),
but not with clinical disease activity (P¼ 0.2730; Supple-
mentary Tables S2–S4 online).
Most anti-Dsg1 IgG autoantibodies in mucocutaneous-type PV
sera recognize the N-terminal region of Dsg1 EC domains
Next, we analyzed the recognition of Dsg1 epitopes by
autoantibodies in 46 serum samples from 15 cases of
mucocutaneous-type PV with different clinical disease
activity levels (Supplementary Table S3 online). All 46 serum
samples reacted with the full-length EC domain of Dsg1, but
not with Dsg2 (Figure 2b). Of these PV sera, 45 (97.8%)
reacted with the EC1 domain of Dsg1, 12 (26.1%) with EC2, 4
(8.7%) with EC3, 2 (4.3%) with EC4, and 3 (6.5%) with EC5.
The reactivity of mucocutaneous-type PV sera to the EC1
domain of Dsg1 was significantly higher than that to the
EC2–5 domains (Po0.0001), whereas the reactivity to the
EC2 domain of Dsg1 was not. Thus, the EC1 domain of Dsg1
was the major epitope recognized by anti-Dsg1 IgG
autoantibodies. We also established the Dsg1 epitope profiles
for these 46 PV sera obtained at different stages of clinical
disease activity (Table 1d). Again, the major epitopes always
resided on the N-terminal domain (EC1 domain) of Dsg1 at
every stage of clinical disease activity, and their distribution
was almost the same no matter which clinical disease activity
level was tested. We found that 14 sera (30.4%) recognized
epitopes on the multiple EC domains of Dsg1, of which 10
(21.7%) reacted with two, 2 (4.3%) with three, and 2 (4.3%)
with four EC domains (Table 1e). No sera were found to react
with all five EC domains. A total of 32 sera (69.6%) reacted
with only one of the EC domains of Dsg1, 31 (67.4%) reacted
only with the EC1 domain, and 1 (2.2%) only with the EC2
domain. No sera reacted only with the Dsg1 EC3, EC4, or
EC5 domain (Table 1f).
Epitope profiles of mucocutaneous-type PV
We compared the epitope profiles of anti-Dsg1 and anti-Dsg3
IgG autoantibodies in 15 cases (46 sera) of mucocutaneous-
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type PV (Supplementary Table S3 online). Both anti-Dsg1 and
anti-Dsg3 IgG autoantibodies reacted predominantly with the
EC1 domain, whereas epitope profiles for the other domains
did not always show the same pattern for Dsg1 or Dsg3. Of
the 46 sera, 38 reacted with the EC1 domain of both Dsg1
and Dsg3. Only five sera showed the same epitope pattern
with Dsg1 and Dsg3.
Epitope spreading is rare in PV
We next analyzed whether epitope spreading occurred at any
time over the disease course. At every clinical disease activity
level, most anti-Dsg3 IgG autoantibodies predominantly
recognized the EC1 domain, and no intramolecular epitope
shift was apparent in 51 (96.2%) of 53 PV cases (Figure 3a
and Supplementary Table S2 online). We found only two
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Figure 1. Calcium-dependent pemphigus foliaceus (PF) and pemphigus vulgaris (PV) epitopes analyzed by new domain-swapped molecules. (a) Full-length
recombinant proteins for the extracellular (EC) domains of human desmoglein 1 (Dsg1) (rDsg1), Dsg2 (rDsg2), Dsg3 (rDsg3), and 10 domain-swapped molecules
(Dsg3 EC1/Dsg2–Dsg3 EC5/Dsg2 and Dsg1 EC1/Dsg2–Dsg1 EC5/Dsg2). (b) Culture supernatants stained with anti-E tag mAb: rDsg1 (lane 1), rDsg2 (lane 2),
rDsg3 (lane 3), Dsg3 EC1/Dsg2 (lane 4), Dsg3 EC2/Dsg2 (lane 5), Dsg3 EC3/Dsg2 (lane 6), Dsg3 EC4/Dsg2 (lane 7), and Dsg3 EC5/Dsg2 (lane 8). (c) Culture
supernatants stained with anti-E tag mAb: rDsg1 (lane 1), Dsg1 EC1/Dsg2 (lane 2), Dsg1 EC2/Dsg2 (lane 3), Dsg1 EC3/Dsg2 (lane 4), Dsg1 EC4/Dsg2 (lane 5),
and Dsg1 EC5/Dsg2 (lane 6). (d) Dsg1/Dsg2 and Dsg3/Dsg2 domain–swapped molecules pretreated with calcium (Ca: (þ )) or EDTA (Ca: ()) detected by
immunoprecipitation–immunoblotting. EC1-swapped molecules with (arrows) and without (arrowheads) prosequence are marked.
1160 Journal of Investigative Dermatology (2012), Volume 132
B Ohyama et al.
Epitope Spreading Is Rare in Pemphigus
patients (3.8%) manifesting apparent Dsg3 epitope spreading
during the disease course (Figure 3b), and none for Dsg1 in
any of the 15 PV cases (Supplementary Tables S2 and S3
online). In 13 mucocutaneous-type PV cases (44 sera), in
which both anti-Dsg3 and anti-Dsg1 IgG autoantibodies were
present, no intermolecular epitope spreading between Dsg1
and Dsg3 was apparent (Supplementary Table S3 online). In
addition, we found that, in some PV patients, Dsg3 ELISA
reactivity and clinical activity did not correlate well
(Supplementary Tables S2–S4 online). Therefore, we have
analyzed the possible epitope spreading from pathogenic
(i.e., EC1–3) to nonpathogenic epitopes (EC4–5) for cases in
which Dsg ELISA index score did not decrease even after
clinical improvement was obtained. However, statistically, it
was not the case (P¼1.000 for both anti-Dsg3 and anti-Dsg1
antibodies).
Epitope profiles of paraneoplastic pemphigus
Paraneoplastic pemphigus (PNP) is a rare autoimmune
blistering disease associated with neoplasia (Amagai et al.,
1998; Ohyama et al., 2001). All 14 PNP sera tested reacted
with the EC1 domain of Dsg3. Intriguingly, 12 (85.7%) PNP
sera reacted with EC4 (Figure 4a and Table 1g). The reactivity
to the EC4 domain of Dsg3 in PNP was comparable to that to
the EC1 domain (P¼1.00), but was significantly higher than
that to the EC5 domain (P¼ 0.0092).
Epitope profiles of pemphigus herpetiformis
Herpetiform pemphigus (HP) is a pemphigus variant with
clinical features of dermatitis herpetiformis and immunologi-
cal features of pemphigus (Kubo et al., 1997; Ishii et al.,
1999; Seitz et al., 1999). Of the 19 HP cases, 15 possessed
only anti-Dsg1 IgG autoantibodies, 4 had only anti-Dsg3 IgG
autoantibodies, and 2 had both; although one serum (#15)
did not react to the full-length Dsg3, it reacted to its EC1–3
domains (Figure 4b). The major epitopes in 15 Dsg1-reactive
HP sera tested were present on the EC1 domain of Dsg1,
whereas EC2, EC3, and EC4 domains were also recognized
by one-third of these sera (Figure 4b and Table 1h). All six
sera from Dsg3-reactive HP cases reacted with both EC1 and
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Figure 2. Epitope profiles of pemphigus vulgaris (PV). (a) Anti-desmoglein 3 (Dsg3) IgG antibodies preferentially bind to the N-terminal extracellular (EC)
domains of Dsg3. All 212 pemphigus vulgaris (PV) sera reacted with the full-length EC domain of Dsg3, but none with the full-length Dsg2 EC domain. Of the
212 PV sera, 193 reacted with the Dsg3 EC1 domain, 151 with the EC2 domain, 107 with the EC3 domain, 40 with the EC4 domain, and 26 with the EC5
domain. (b) Anti-Dsg1 IgG antibodies preferentially bind to the N-terminal EC domains of Dsg1. Of the 46 PV sera, 45 reacted with the EC1 domain of Dsg1, 12
with the EC2 domain, 4 with the EC3 domain, 2 with the EC4 domain, and 3 with the EC5 domain. *Po0.0001, #not significant. IB, immunoblotting;
IP, immunoprecipitation; NHS; normal human serum.
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Table 1. Epitope profiles of Dsg3 and Dsg1 in PV, PNP, and HP
(a) Epitope profile of Dsg3 at all clinical stages
Recombinant proteins
EC domains of Dsg3
Clinical activity Dsg3 Dsg2 EC1 EC2 EC3 EC4 EC5
Active (%) (n=85) 85 (100) 0 (0) 78 (91.8) 61 (71.8) 38 (44.7) 14 (16.5) 12 (14.1)
Moderate (%) (n=60) 60 (100) 0 (0) 52 (86.7) 42 (70.0) 29 (48.3) 11 (18.3) 6 (10.0)
Remission (%) (n=67) 67 (100) 0 (0) 63 (94.0) 48 (71.6) 40 (59.7) 15 (22.4) 8 (11.9)
Total (%) (n=212) 212 (100) 0 (0) 193 (91.0) 151 (71.2) 107 (50.5) 40 (18.9) 26 (12.3)
(b) PV sera recognizing on multiple EC domain of Dsg3
Number of domains recognized epitopes
Clinical activity Two Three Four Five
Active (%) (n=64) 25 25 13 1
Moderate (%) (n=46) 22 15 8 1
Remission (%) (n=54) 16 24 13 1
Total (%) (n=164) 63 64 34 3
(c) PV sera recognizing on single EC domain of Dsg3
Number of domains recognized epitopes
Clinical activity EC1 EC2 EC3 EC4 EC5
Active (%) (n=21) 18 2 1 0 0
Moderate (%) (n=14) 11 2 1 0 0
Remission (%) (n=13) 11 1 1 0 0
Total (%) (n=48) 40 5 3 0 0
(d) Epitope profile of Dsg1 at all clinical stages
Recombinant proteins
EC domains of Dsg1
Clinical activity Dsg1 Dsg2 EC1 EC2 EC3 EC4 EC5
Active (%) (n=20) 20 (100) 0 (0) 19 (95.0) 4 (20.0) 1 (5.0) 0 (0) 2 (1.0)
Moderate (%) (n=18) 18 (100) 0 (0) 18 (100) 6 (33.0) 0 (0) 0 (0) 0 (0)
Remission (%) (n=8) 8 (100) 0 (0) 8 (100) 2 (25.0) 3 (37.5) 2 (25.0) 1 (12.5)
Total (%) (n=46) 46 (100) 0 (0) 45 (97.8) 12 (26.1) 4 (8.7) 2 (4.3) 3 (6.5)
(e) PV sera recognizing on multiple EC domain of Dsg1
Number of domains recognized epitopes
Clinical activity Two Three Four Five
Active (%) (n=4) 3 0 1 0
Moderate (%) (n=6) 6 0 0 0
Remission (%) (n=4) 1 2 1 0
Total (%) (n=14) 10 2 2 0
Table 1 continued on following page
1162 Journal of Investigative Dermatology (2012), Volume 132
B Ohyama et al.
Epitope Spreading Is Rare in Pemphigus
EC2 domains, and five reacted with the EC3 domain (Figure
4b). One serum reacted with the EC1, EC2, EC3, and EC4
domains of Dsg3. The reactivity to the EC1 domain of Dsg1
(or Dsg3) in HP was comparable to that to the EC2–4 domains
of Dsg1 (or Dsg3) (Dsg1 EC1 vs. EC2: P¼0.1013, EC1 vs.
EC3: P¼0.2417, EC1 vs. EC4: P¼0.1013; Dsg3 EC1 vs.
EC2: P¼ 1.0000, EC1 vs. EC3: P¼1.0000, EC1 vs. EC4:
P¼0.0606), but was significantly higher than that to the EC5
domain of Dsg1 (or Dsg3; Dsg1 EC1 vs. EC5: P¼0.0005,
Dsg3 EC1 vs. EC5: P¼ 0.0087) (Figure 4). Thus, HP sera
recognized a broader range of epitopes than PV.
DISCUSSION
This study documented the rarity of epitope spreading after
the onset of disease in PV. At every clinical activity level, the
major Dsg3 epitopes remained in the EC1–2 domains, and the
epitope profile was essentially identical in most cases.
Furthermore, in mucocutaneous-type PV, dominant epitopes
of Dsg1 were present in EC1 but not in the EC2–5 domains.
We concluded that there was no significant alteration in
epitope profiles over the disease course. In addition, we
showed that PNP and HP showed broader epitope distribu-
tion compared with classical pemphigus. Moreover, we
showed for the first time that calcium-dependent conforma-
tional epitopes on human Dsg1 and Dsg3 recognized by
pemphigus IgG autoantibodies are located within the EC1–3
domains, whereas EC4 and EC5 are calcium stable, as had
been suggested in animal models (Tsunoda et al., 2003).
The new domain-swapped molecules described here are
useful for epitope mapping and for analyzing epitope
spreading. Our new strategy has several advantages. First,
the swapped domains have similar structures but distinct
epitopes. Hence, they allow precise mapping of the
conformational epitopes embedded in the three-dimensional
molecular structure (Mu¨ller et al., 2006, 2008). Second, by
using a disease-irrelevant Dsg2 as the backbone of the
domain-swapped molecules, one can analyze the epitopes
recognized by anti-Dsg3 IgG autoantibodies (or anti-Dsg1
IgG autoantibodies) without the influence of the presence
of anti-Dsg1 IgG autoantibodies (or anti-Dsg3 IgG autoanti-
bodies, respectively). Previously, Dsg/Dsg1-swapped mole-
cules were used to analyze intra- and intermolecular epitope
spreading (Futei et al., 2000; Sekiguchi et al., 2001; Li et al.,
2003; Salato et al., 2005). However, although Dsg3 and Dsg1
do not have common structure, the Dsg3/Dsg1-swapped
molecule system did not allow us to analyze intra- and
(f) PV sera recognizing on single EC domain of Dsg1
Number of domains recognized epitopes
Clinical activity EC1 EC2 EC3 EC4 EC5
Active (%) (n=16) 15 1 0 0 0
Moderate (%) (n=12) 12 0 0 0 0
Remission (%) (n=4) 4 0 0 0 0
Total (%) (n=32) 31 1 0 0 0
(g) Epitope distributions on Dsg3 in 14 PNP cases
Recombinant proteins
EC domains of Dsg3
Dsg3 Dsg2 EC1 EC2 EC3 EC4 EC5
PNP (%) (n=14) 14 (100) 0 (0) 14 (100) 8 (57.1) 10 (71.4) 12 (85.7) 3 (21.4)
(h) Epitope distributions on Dsg1 for 15 sera and Dsg3 for 6 sera in HP cases
Recombinant proteins
EC domains of Dsg1
Dsg1 Dsg2 EC1 EC2 EC3 EC4 EC5
HP (%) (n=15) 15 (100) 0 (0) 12 (80.0) 5 (33.3) 6 (40.0) 5 (33.3) 1 (6.7)
Dsg2 Dsg3 Extracellular domains of Dsg3
EC1 EC2 EC3 EC4 EC5
HP (%) (n=6) 0 (0) 5 (83.3) 6 (100) 6 (100) 5 (83.3) 1 (16.7) 0 (0)
Abbreviations: Dsg, desmoglein; EC, extracellular; HP, herpetiform pemphigus; PNP, paraneoplastic pemphigus; PV, pemphigus vulgaris.
Table 1. Continued
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intermolecular epitope spreading precisely, namely in muco-
cutaneous-type PV, in which anti-Dsg1 and anti-Dsg3
antibodies are present simultaneously in the blood. The
advantage of the method reported here is depicted in Figure 5.
Our results suggest that human autoimmunity conforms to
the concept of ‘‘original antigenic sin’’, i.e., domination of
the immune response by the initial epitope, which does not
change over time. We recently also demonstrated that
epitope spreading is rare in PF (Chan et al., 2010). Our
results are in agreement with a previous study in which
epitope shift rarely occurred in PV (Futei et al., 2000). Our
results are not in agreement with previous studies that support
epitope spreading in pemphigus (Li et al., 2003; Salato et al.,
2005). Li et al. (2003) showed the possible intramolecular
epitope spreading from EC5 at onset to EC1 and EC2 in active
stage, and then toward EC5 in remission in endemic PF. As
Chan et al. (2010) suggested that epitope shift did not occur
in nonendemic PF, the discrepancy may be due to the
difference between endemic and nonendemic PF. Salato
et al. (2005) reported that intramolecular epitope spreading
from EC2–5 to the EC1 domain of Dsg3 occurred and was a
critical step for intermolecular epitope shift from Dsg3 to
Dsg1. However, it is a questionable idea, because their claim
was based on the result of only one representative case out of
three mucosal dominant-type PV patients who transitioned
to mucocutaneous-type PV, and they used the Dsg3/Dsg1-
swapped system. The present study does not exclude the
possibility of autoimmunity initiated by bystander activation,
molecular mimicry, or release of cryptic epitopes before
disease onset (Miller et al., 1997; Horwitz et al., 1998; Olson
et al., 2001).
Our present results revealed a unique Dsg3 epitope
distribution in PNP and HP. The EC4 domain in PNP and
EC1–3 domains in HP were frequently recognized by
autoantibodies, although major Dsg3 epitopes in both PNP
and HP were still found in N-terminal EC domains. The result
for PNP is consistent with a previous study using competition
ELISA with domain-swapped Dsg3/Dsg1 molecules (Futei
et al., 2003). The different autoantibody profiles between
these diseases and PV may contribute to their unique
clinicohistopathological characteristics.
There are limitations to our study. First, it is impossible to
evaluate epitope spreading before the onset of disease.
Spreading from viral to self-epitopes has been shown in a
virus-induced autoimmune disease model (Miller et al.,
1997). However, there is no consensus that tissue-specific
autoimmune diseases develop during persistent viral or other
infections (Horwitz et al., 1998; Zhao et al., 1998; Olson
et al., 2001). Second, we cannot exclude the fact that
treatment influenced epitope spreading, when using immu-
nosuppressives, apheresis, or intravenous immunoglobulin,
all of which could impair epitope spreading. Third, there are
technical issues in quantitative evaluation of autoantibodies
when using IP–IB on sera with low Dsg titers. Fourth, it is
No apparent epitope spreading
(Cases 1, 3, and 31)
Apparent epitope spreading
(Cases 4 and 10)
Case 1 Case 4
Case 10Case 3
Case 31
Disease
activity
Active 126
178Active
Remission
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Figure 3. Epitope shift in the target antigens for anti-desmoglein 3 (Dsg3) IgG antibodies occurs rarely over the disease course. (a) Most cases (n¼51)
had no epitope shift. (b) Epitope profiles for anti-Dsg3 IgG antibodies from pemphigus vulgaris (PV) patients 4 and 10. Only these two PV sera showed
apparent epitope shift for anti-Dsg3 IgG target antigens. Disease activity and anti-Dsg3 ELISA index for each serum are also shown at the left of each figure.
EC, extracellular.
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impossible to analyze the intra-domain epitope spreading
within each EC domain by this study.
In conclusion, we have documented the rarity of epitope
spreading in PV. Therefore, targeting treatments to the
N-terminal domains of Dsg3/Dsg1 should be promising to
control PV.
MATERIALS AND METHODS
Human sera
All studies followed the guidelines of the Medical Ethics Committees
of both Kurume University School of Medicine and Keio University
School of Medicine, conducted according to the Declaration of
Helsinki Principles. All participants provided informed consent. A
total of 212 sera were obtained from 31 patients with mucocuta-
neous-type PV and 22 with mucosal dominant-type PV confirmed by
clinical, histological, and immunological findings. Clinical disease
activity was defined according to an arbitrary score as follows:
active, 430% of the skin affected by lesions, and functional
impairment; moderate, 10–30% skin involvement but no functional
disability; remission, no active clinical skin lesions for at least 1
month under treatment witho5mg per day prednisolone or without
any treatment. The interval between measurements was 376 days on
average (SD 526).
IP:
rDsg3
rDsg2
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Dsg1 EC1/Dsg2
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Figure 4. Epitope profiles of atypical pemphigus. (a) All 14 PNP sera reacted with the full-length desmoglein 3 (Dsg3) extracellular (EC) domain, but none with
the full-length EC domain of Dsg2. *P¼ 0.0001, **Po0.001, and #not significant. All 14 PNP sera reacted with the EC1 domain of Dsg3, 9 with EC2, 10 with
EC3, 12 with EC4, and 3 with EC5 (b). In the 15 sera from herpetiform pemphigus (HP) cases, the major epitopes were present on the Dsg1 EC1 domain.
However, six HP patients had anti-Dsg3 IgG autoantibodies, and all six sera reacted with EC1 and EC2 domains; five reacted with the EC3 domain. All six sera
reacted most strongly with the EC2 domain of Dsg3. *Po0.001, #not significant. IP, immunoprecipitation.
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In all, 19 HP and 14 PNP cases were diagnosed by clinical,
histological, and immunological findings. All 14 PNP cases
possessed IgG autoantibodies against envoplakin and periplakin as
assessed by immunoblotting using human epidermal extracts
(Hashimoto et al., 1995). All sera were assayed by ELISA using
recombinant Dsg1 and Dsg3 baculoprotein as substrates (Ishii et al.,
1997; Amagai et al., 1999) and 1,600 dilutions of patients’ sera
(Cheng et al., 2002).
Preparation of the plasmid constructs
Production of recombinant Dsg1 (rDsg1), Dsg2 (rDsg2), and Dsg3
(rDsg3) has been described elsewhere (Amagai et al., 1994; Ishii
et al., 1997; Ota et al., 2003). To produce the plasmid constructs, we
used an overlap-extension PCR technique. For example, to prepare
the Dsg3 plasmid construct with the EC3 domain swapped, first we
amplified the EC1–2 domains of Dsg2, the EC3 domain of Dsg3, and
the EC4–5 domains of Dsg2. The cDNAs for the different domains of
Dsg2 and Dsg3 were amplified with appropriate primers (Supple-
mentary Table S1 online) using pQE-hDsg2 and pQE-hDsg3
(Qiagen, Hilden, Germany) as templates. Next, we annealed the
PCR products of EC1–2 of Dsg2 and EC3 of Dsg3 several (5 or 7)
times, and amplified them with appropriate primers. We then
annealed the annealed/amplified products of EC1–2 of Dsg2 and EC3
of Dsg3 and the PCR product of EC4–5 of Dsg2 several times, and
amplified them with appropriate primers. Plasmid constructs of the
EC1 and EC5 domains were produced by the two-step method of
annealing and extension, whereas the constructs of EC2, EC3, and
EC4 domains were produced by a three-step method of annealing
and extension. The PCR products of Dsg3 domain–swapped
molecules were digested with NcoI/XhoI and ligated to NcoI/XhoI-
cut pQE-Tri expression vector (pQE-hDsg2). These constructs
contained an E-tag and a His-tag at their C-terminal region.
Sequences were confirmed using an ABI310 genetic analyzer
(Applied Biosystems, Carlsbad, CA). Plasmid constructs were
designated pQE-Dsg3 EC1/Dsg2, pQE-Dsg3 EC2/Dsg2, pQE-Dsg3
EC3/Dsg2, pQE-Dsg3 EC4/Dsg2, and pQE-Dsg3 EC5/Dsg2.
Domain-specific swapped Dsg1 constructs were prepared
according to the previous report (Chan et al., 2010), and designated
pQE-Dsg1 EC1/Dsg2, pQE-Dsg1 EC2/Dsg2, pQE-Dsg1 EC3/Dsg2,
pQE-Dsg1 EC4/Dsg2, and pQE-Dsg1 EC5/Dsg2.
Protein production by baculovirus expression
Plasmids were co-transfected with Sapphire baculovirus DNA
(Orbigen, San Diego, CA) and Cellfectin reagent (Invitrogen, San
Diego, CA) into cultured insect Sf9 cells. A high titer of recombinant
baculovirus stock was obtained after several rounds of re-amplifica-
tion. High Five cells (Invitrogen) cultured in serum-free EX Cell 405
medium (JRH Biosciences, Lenexa, KS) were infected with the
recombinant viruses and incubated at 27 1C for 3 days; domain-
swapped molecules were secreted into the culture supernatant and
stored at 80 1C after cell debris removal by centrifugation. The
Dsg3 domain–swapped baculoproteins were designated Dsg3 EC1/
Dsg2, Dsg3 EC2/Dsg2, Dsg3 EC3/Dsg2, Dsg3 EC4/Dsg2, and Dsg3
EC5/Dsg2. The Dsg1 domain–swapped baculoproteins were desig-
nated Dsg1 EC1/Dsg2, Dsg1 EC2/Dsg2, Dsg1 EC3/Dsg2, Dsg1 EC4/
Dsg2, and Dsg1 EC5/Dsg2.
Immunoblotting
Culture supernatants containing recombinant baculoproteins were
fractionated by SDS-PAGE. Mouse anti-E tag mAb (Pharmacia
Biotech, Uppsala, Sweden) was used as a primary antibody and
alkaline phosphatase–conjugated goat anti-mouse IgG antibody
(Zymed Laboratories, San Francisco, CA) as the secondary antibody.
IP–IB
Culture supernatants containing recombinant baculoproteins were
incubated with PV sera and then precipitated with protein G-
Sepharose (Amersham Biosciences, Uppsala, Sweden) overnight.
After centrifugation, the precipitates were resuspended in SDS
sample buffer and boiled for 2minutes. After centrifugation, the
supernatants were applied to SDS-PAGE, and proteins were
transferred to a polyvinylidene difluoride membrane (Millipore,
Bedford, MA). The precipitated recombinant baculoproteins were
reacted with mouse horseradish peroxidase–conjugated anti-E tag
mAb (Amersham Biosciences), and then with the chemilumines-
cence reagent (PerkinElmer Life Sciences, Boston, MA). Finally, the
film (Kodak Biomax, Rochester, NY) was exposed to the poly-
vinylidene difluoride membrane.
EDTA treatment
A volume of 50 ml of 0.5M EDTA was added to 400 ml culture
supernatants containing the five domain-swapped molecules and
incubated at 4 1C for 1 h. The culture supernatants with EDTA were
dialyzed against TBS (). For positive controls with calcium, 400ml
of culture supernatants was added to 50 ml of TBS () supplemented
with 0.5mM CaCl2, and dialyzed in TBS () with 0.5mM CaCl2.
Subsequently, culture supernatants with or without calcium treat-
ment were analyzed by IP–IB.
Statistical analysis
The associations among distributions of reactivity of ECs were
assessed by the w2 test with Bonferroni correction. The associations
Domain-swapped baculoproteins
Epitope
analysis
Less
informative
More
informative
More
informative
(1) Dsg3/Dsg1 domain–swapped molecules
(2)
(3)
Dsg3/Dsg2 domain–swapped molecules
Dsg1/Dsg2 domain–swapped molecules
EC1
Dsg3 Dsg1
EC2 EC3 EC4 EC5 lg His
EC1
Dsg3 Dsg2
Dsg2
Anti-Dsg1 lgG Anti-Dsg3 lgG
Dsg1
EC2 EC3 EC4 EC5 E His
EC1 EC2 EC3 EC4 EC5 E His
Figure 5. Schematic diagram of the advantages of new desmoglein 1 (Dsg1)/
Dsg2 and Dsg3/Dsg2 domain–swapped molecules. In mucocutaneous-type
pemphigus vulgaris, it is difficult to analyze more informative epitopes
using Dsg3/Dsg1 domain–swapped molecules, because both anti-Dsg1
autoantibodies and anti-Dsg3 autoantibodies bind to the same swapped
molecules (1). Dsg2 backbone new domain–swapped molecules are able
to analyze the epitopes without the influence of other antibodies (2)
and (3).
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between clinical improvement with high ELISA index score and shift
from EC1–3 to EC4–5 were assessed by the Fisher exact test.
Relationships of reactivity of ECs with clinical disease activity and
ELISA index score were assessed by the generalized estimation
equation method with AR1 working correlation matrix. Disease
activity was treated as an ordinal variable. A P-value o0.01 was
considered statistically significant.
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